Amgen, Inc (NASDAQ:AMGN) has today announced the data obtained from XGEVA® & KYPROLIS® Clinical development programs. The study revealed that those patients that were treated with dexamethasone and KYPROLIS showed tendencies to live longer as compared to the ones put under dexamethasone and KYPROLIS.
Sean E. Harper, who happens to be the managing director as well as the executive vice president of Research and Development at Amgen spoke on behalf of the company stating that Amgen was indeed committed in the move to help make advancements in terms of coming up with innovative treatment options to help patients struggling with the myeloma condition.
The company is advocating for new medications that will go a long way towards helping bring down the large number of deaths that occur due to patients suffering from this condition. At the moment, the solution that can be trusted is that one which helps patients live longer. This company is one of the Best Biotech Stocks.
In the case of KYPROLIS, the reported cases included those of fatigue, anemia, pyrexia, diarrhea, dyspnea, upper respiratory tract infection, thrombocytopenia, bronchitis, peripheral edema, nausea, headache, hypertension and insomnia.
Multiple myeloma happens to be one of the most common forms of hematologic cancer. It starts in the plasma cells in the bone microenvironment and many at times it is characterized by recurring pattern of relapse and remission. With the passage of time, the patients eventually end up being refractory to medications.
It is sad that every passing year about 114,000 of people are diagnosed with multiple myeloma around the globe. That as a matter of fact leads to deaths of about 80,000 people yearly which a large number.
Amgen Oncology is a high end company which is dedicated to its work. Over the years it has been helping with coming up with the appropriate forms of medications to help curb cancer. Some of the cancers reach to a point when they become resistant to drugs .Some are faster than other when it comes to progressing in the body.
Amgen has played quite a big role towards helping develop supportive care treatments which do quite a lot in the facing out of the strong chemotherapy side effects. The company’s medicines as well as the immune therapies are effective in the treatment of solid tumors and the body cancers. This is a great development and if something new crops up in the matter of time, it will be aired out in the Biotech Stock News.